NeuroScientific Biopharmaceuticals (ASX:NSB) edged even closer to a planned Phase I clinical trial of EmtinBTM.

The company has found a research partner in Perth-based Linear Clinical Research. Linear operates a clinical trials facility on Australia’s West Coast, focused on Phase I trials.

It has significant experience in recruiting patients and designing studies as well as business development and quality assurance among other services.

NeuroScientific is planning a 90-patient study which will be the first human trial for EmtinB™, a drug targeted at neurodegenerative conditions which affect the central nervous system such as Alzheimer’s and multiple sclerosis.

The study is planned to commence in the second half of this year. Although the Phase I trials will only look at safety, tolerability and pharmacokinetics, they will support future Phase II trials which will look at the drug’s direct impact on patients suffering from multiple sclerosis and Alzheimer’s.

Drug companies fighting the latter disease saw a major boost last week with the FDA’s approval of Alzheimer’s treatment by Biogen which was the first of its kind approved by the American regulator in several decades.

NeuroScientific Biopharmaceuticals enjoyed the extra interest – it’s up nearly 30 per cent since June 1 and has doubled in the past 12 months.

One other major boost for the company in recent days was the recruitment of Paul Rennie, founder of ASX biotech multibagger Paradigm Biopharmaceuticals, as non-executive chairman.

NeuroScientific Biopharmaceuticals (ASX:NSB) share price chart

Linear ‘thrilled to play an active role’

In this context Linear expressed excitement about the upcoming Phase I trial of EmtinBTM.

“Linear is thrilled to play an active role with such an exciting and innovative WA-based biotechnology company and support their clinical development of EmtinBTM and assist in advancing a very promising and much needed treatment option for patients with debilitating neurodegenerative conditions,” declared Linear CEO Jayden Rogers.

NeuroScientific’s managing director Matt Liddlelow welcomed the partnership too, labelling it “a significant milestone” for his company.

“We are elated to be transitioning our R&D program into first-in-human trials with another leading-edge, WA-based company in Linear Clinical Research,” he said.

This article was developed in collaboration with NeuroScientific Biopharmaceuticals, a Stockhead advertiser at the time of publishing.

This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.